期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

慢性粒细胞性白血病靶向治疗时代异基因造血干细胞移植的角色 被引量：3

下载PDF
导出
摘要 进入21世纪以来,革命性的酪氨酸激酶抑制剂(tyrosine kinases inhibitors,TKIs)的发展显著改变了慢性粒细胞性白血病(chronic myelogenous leukemia,CML)患者的治疗方式。TKIs成为CML慢性期(CP)患者的一线治疗药物,接受异基因造血干细胞移植(allogeneic hematopoietic stem cell transplantation,Allo-HSCT)的CML患者例数较前显著下降。表面看来,TKIs的治疗冲击了Allo-HSCT的地位,似乎二者处于对立的角色,而实际上,TKIs的应用促进了Allo-HSCT技术在CML中的应用,Allo-HSCT技术的进步以及与TKIs治疗相辅相成,对于攻克CML难题展现了新的前景。
作者 何雪峰 张翔 孙爱宁 吴德沛
机构地区 苏州大学附属第一医院血液科 江苏省血液研究所 卫生部血栓与止血重点实验室
出处 《中国医学前沿杂志（电子版）》 2012年第5期44-50,共7页 Chinese Journal of the Frontiers of Medical Science(Electronic Version)
基金 卫生部科技教育司卫生公益性行业科研专项经费项目(项目编号:201202017) 江苏高校优势学科建设工程资助项目(PAPD) 江苏省临床医学中心(编号:ZX201102)
关键词 CML 患者 伊马替尼 HSCT 慢性粒细胞性白血病 慢性髓质性白血病 异基因造血干细胞移植 脐血移植 进展期 靶向治疗
分类号 R733.7 [医药卫生—肿瘤]
  • 相关文献

参考文献54

  • 1Gratwohl A;Baldomero H;Passweg J.Hematopoietic stem cell transplantation for hematological malignancies in Europe[J]Leukemia:Official Journal of the Leukemia Society of America,Leukemia Research FundU.K2003(05):94t-959.
  • 2O'Brien S G;Guilhot F;Larson R A.Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia[J]New England Journal of Medicine,2003(11):994-1004.
  • 3Hasford J;Pfirrmann M;Hehlmann R.A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa.Writing Committee for the Collaborative CML Prognostic Factors Project GroupWriting Committee for the Collaborative CML Prognostic Factors Project Group</a>[J].Journal of the National Cancer Institute,1998(11):850-858.
  • 4Gratwohl A;Baldomero H;Frauendorfer K.EBMT activity survey 2004 and changes in disease indication over the past 15 years[J],2006(12).
  • 5Myojo T;Hino N.Complete remission from chronic myelogenous leukemia--blastic crisis caused by reduced intensity stem cell transplantation following partial remission due to imatinib[J]Internal Medicine,2004(02):126-130.
  • 6Hehlmann R;Berger U;Pfirrmann M.Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia[J]Blood,2007(11):4686-4692.
  • 7Giralt S A;Arora M;Goldman JM.Impact of imatinib therapy on the use of allogcneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia[J]British Journal of Haematology,2007(05):461-467.
  • 8Baccarani M;Saglio G;Goldman J.Evolving concepts in the management of chronic myeloid leukemia:recommendations from an expert panel on behalf of the European LeukemiaNet[J],2006(06).
  • 9Bornhauser M;Kroger N;Schwerdtfeger R.Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib:a retrospective multicentre study[J]European Journal of Haematology,2006(01):9-17.
  • 10Menzel H;von Bubnoff N;Hochhaus A.Successful allogeneic stem cell transplantation in second chronicphase CML induced by the tyrosine kinase inhibitor nilotinib (AMN107) after blast crisis under imatinib[J]Bone Marrow Transplantation,2007(01):83-84.

二级参考文献14

  • 1Kernan NA, Bartsch G, Ash RC, et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med, 1993, 328: 593-602.
  • 2Beatty PG. Marrow transplantation using volunteer unrelated donors in a comparison of mismatched family donor transplants:a Seattle perspective. Bone Marrow Transplant, 1994, 14 Suppl 4: S39-41.
  • 3Aversa F, Tabilio A, Velardi A, et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med,1998, 339: 1186-1193.
  • 4Mineishi S, Longo WL, Atkinson ME, et al. Addition of highdose Ara-C to the BMT conditioning regimen reduces leukemia relapse without an increase in toxicity. Bone Marrow Transplant, 1999, 23: 1217-1222.
  • 5Hassan HT,Stockschlader M,Schleimer B,et al. Comparison of the content and subpopulation of CD3 and CD34 positive cells in bone marrow harvest and G-CSF-mobilized peripheral blood leukapheresis products from healthy adult donors. Transplant Immunol, 1996,
  • 6Mielcarek M, Roecklein BA, Torok-Storb B. CD14+- cells in GCSF mobilized peripheral blood mononuclear cells induce secretion of interleukin-6 and G-CSF by marrow stroma. Blood,1996, 87: 574-580.
  • 7Pan L, Delmonte J Jr, Jalonen CK, et al. Pretreatment of donor mice with granulocyte-colony stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood, 1995,86 :
  • 8Arpinati M, Loken M, Anasetti C. G-CSF mobilizes type 2-derdritic cells rather than type 1-dendritic cells. Blood, 1998, 92Suppl 1: 111a.
  • 9Ji SQ, Chen HR, Wang HX, et al. Comparison of outcome of allogeneic bone marrow transplantation with and without granulocyte colony-stimulating factor (lenograstim) donor-marrow priming in patients with chronic myelogenous leukemia. Biol Blood Marrow Tran
  • 10Ji SQ, Chen HR, Xun CQ, et al. The effect of G-CSF stimulated donor marrow on engraftment and incidence of graft-versushost disease in allogeneic bone marrow transplantation. Clin Transplant, 2001, 15: 317-323.

共引文献70

同被引文献39

  • 1杨慧,马立元,闫金松,梁辉.慢性粒细胞白血病急变机制的研究进展[J].中国医学前沿杂志（电子版）,2011,3(3):39-42. 被引量：1
  • 2韩伟,陆道培,黄晓军,刘开彦,陈欢,许兰平,刘代红,江倩,陈育红,路瑾,王静波,吴彤,董陆佳,任汉云.HLA配型不合造血干细胞移植GIAC方案100例临床分析[J].中华血液学杂志,2004,25(8):453-457. 被引量：68
  • 3Jain N,van Besien K.Chronic myelogenous leukemia:role of stem cell transplant in the imatinib era.Hematol Oncol Clin North Am,2011;25(5):1025-1048.
  • 4Wingard JR,Majhail NS,Brazauskas R,et al.Long-term survival and late deaths after allogeneic hematopoietic cell transplantation.J Clin Oncol,2011;29(16):2230-2239.
  • 5Mughal TI,Schrieber A.Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase.Biologics,2010;2(4):315-323.
  • 6Kerkela R,Grazette L,Yacobi R,et al.Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.Nat Med,2006,12(8):908-916.
  • 7Hu W,Lu S,Mc Alpine I,Jamieson JD,et al.Mechanistic investigation of imatinib-induced cardiac toxicity and the involvement of cAbl kinase.Toxicol Sci,2012;129(1):188-199.
  • 8Rosti G,Martinelli G,Baccarani M.In reply to'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'.Nat Med,2007;13(1):15-16.
  • 9Atallah E,Durand JB,Kantarjian H,et al.Congestive heart failure is a rare event in patients receiving imatinib therapy.Blood,2007;110(4):1233-1237.
  • 10Ribeiro AL,Marcolino MS,Bittencourt HN,et al.An evaluation of the cardiotoxicity of imatinib mesylate.Leuk Res,2008;32(12):1809-1814.

引证文献3

二级引证文献10

中国医学前沿杂志（电子版）
2012年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部